- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.12. | GSK taps a startup for shot at Alzheimer's drug | ||
| 05.12. | Nuvig pulls in $161M to make better immune drugs | ||
| 04.12. | Dewpoint, Mitsubishi partner on ALS drug in deal worth up to $480M | ||
| 04.12. | Atea plans Phase 3 study for hepatitis C drug after mid-stage results | ||
| 04.12. | Novavax sells Czech plant to Novo; Relay licenses out a cancer drug | ||
| 04.12. | Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives | ||
| 04.12. | UnitedHealthcare CEO Brian Thompson fatally shot in NYC | ||
| 04.12. | Lilly's Zepbound beats Novo's Wegovy in high-stakes obesity drug trial | ||
| 03.12. | Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M | ||
| 03.12. | Janux impresses Wall Street with new prostate cancer drug results | ||
| 03.12. | Note from the Editor-in-Chief | ||
| 02.12. | Diabetes advocacy group discourages use of compounded GLP-1 drugs | ||
| 02.12. | Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date | ||
| 02.12. | Novartis wagers billions of dollars on PTC Huntington's drug | ||
| 02.12. | Applied's rare disease drug rejected by FDA | ||
| 02.12. | Are You Using Next-Gen Sequencing to inform AAV product and process quality? Here are 4 reasons you should | ||
| 27.11. | Sarepta rebuilds drug pipeline with Arrowhead deal | ||
| 27.11. | How Intra-Cellular surprised Wall Street by breaking character | ||
| 27.11. | Kronos, Idorsia plan layoffs; PTC shelves ALS drug | ||
| 26.11. | Biden administration proposes Medicare, Medicaid coverage of pricey weight loss drugs | ||
| 26.11. | Amgen obesity drug cuts weight in study, but results miss Wall Street's high mark | ||
| 26.11. | Roche's TIGIT-targeting drug for cancer fails its biggest test | ||
| 26.11. | Roche to buy cell therapy developer Poseida for $1B | ||
| 26.11. | Alector turns to layoffs as Alzheimer's drug fails | ||
| 25.11. | New data could help Merck expand use of cardiovascular drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
